Abstract
Introduction: The imbalance in gut microbiota is contributing to the development and progression of IBS. FMT can improve the gut microbiota, and donor-recipient-matched FMT can help develop individualized treatment plans according to different enterotypes. This study aimed to explore the efficacy of donor-recipient-matched FMT in IBS with predominant diarrhoea (IBS-D) and evaluate its effects on gut microbiota. Methods: Twenty-seven patients with IBS-D were randomly divided into donor-recipient-matched FMT group (group P), random-donor FMT group (group R), and placebo group (group B). All participants received corresponding FMT treatment after filling in IBS-S, IBS-QoL, GSRS, and HADS questionnaires and having their stool samples collected at 4, 8, and 12 weeks after treatment. The improvement in the symptoms and the changes in the bacterial flora were analysed for three groups. Results: The IBS-SSS, IBS-QoL, GSRS, and anxiety scores of group P were significantly lower after treatment (p < 0.05). The IBS-QoL scores of group R were significantly lower after treatment (p < 0.05). Beta diversity analysis showed that the gut microbiota of group P had an obvious trend of classification after treatment. Seven bacterial genera were related to the differences in the IBS-SSS scores before and after treatment. Conclusion: Donor-recipient-matched FMT significantly improved the clinical symptoms, quality of life, and anxiety scores of the patients with IBS-D than random-donor FMT.
Journal Section:
Research Article
References
1.
Sperber
AD
, Dumitrascu
D
, Fukudo
S
, Gerson
C
, Ghoshal
UC
, Gwee
KA
, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review
. Gut
. 2017
;66
(6
):1075
–82
. 2.
Drossman
DA
. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV
. Gastroenterology
. 2016
;150
(6
):1262
–79.e2
. 3.
Dekel
R
, Drossman
DA
, Sperber
AD
. The use of psychotropic drugs in irritable bowel syndrome
. Expert Opin Investig Drugs
. 2013
;22
(3
):329
–39
. 4.
Lee
YJ
, Park
KS
. Irritable bowel syndrome: emerging paradigm in pathophysiology
. World J Gastroenterol
. 2014
;20
(10
):2456
–69
. 5.
Duan
R
, Zhu
S
, Wang
B
, Duan
L
. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review
. Clin Transl Gastroenterol
. 2019
;10
(2
):e00012
. 6.
Mei
L
, Zhou
J
, Su
Y
, Mao
K
, Wu
J
, Zhu
C
, et al. Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
. Bmc Gastroenterol
. 2021
;21
(1
):105
. 7.
Liu
Y
, Zhang
L
, Wang
X
, Wang
Z
, Zhang
J
, Jiang
R
, et al. Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression
. Clin Gastroenterol Hepatol
. 2016
;14
(11
):1602
–11.e5
. 8.
Bonetto
S
, Fagoonee
S
, Battaglia
E
, Grassini
M
, Saracco
GM
, Pellicano
R
. Recent advances in the treatment of irritable bowel syndrome
. Pol Arch Intern Med
. 2021
;131
(7–8
):709
–15
. 9.
Zhang
B
, Yang
L
, Ning
H
, Cao
M
, Chen
Z
, Chen
Q
, et al. A matching strategy to guide donor selection for ulcerative colitis in fecal microbiota transplantation: meta-analysis and analytic hierarchy process
. Microbiol Spectr
. 2023
;11
(1
):e0215921
. 10.
He
J
, He
X
, Ma
Y
, Yang
L
, Fang
H
, Shang
S
, et al. A comprehensive approach to stool donor screening for faecal microbiota transplantation in China
. Microb Cell Fact
. 2021
;20
(1
):216
. 11.
Nusbaum
DJ
, Sun
F
, Ren
J
, Zhu
Z
, Ramsy
N
, Pervolarakis
N
, et al. Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients
. FEMS Microbiol Ecol
. 2018
;94
(9
):fiy133
. 12.
Goll
R
, Johnsen
PH
, Hjerde
E
, Diab
J
, Valle
PC
, Hilpusch
F
, et al. Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome
. Gut Microbes
. 2020
;12
(1
):1794263
. 13.
El-Salhy
M
, Hausken
T
, Hatlebakk
JG
. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS)
. Nutrients
. 2019
;11
(12
):3013
. 14.
Johnsen
PH
, Hilpüsch
F
, Valle
PC
, Goll
R
. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: secondary endpoints of a double blind, randomized, placebo-controlled trial
. Ebiomedicine
. 2020
;51
:102562
. 15.
Francavilla
R
, Piccolo
M
, Francavilla
A
, Polimeno
L
, Semeraro
F
, Cristofori
F
, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial
. J Clin Gastroenterol
. 2019
;53
(3
):e117
–25
. 16.
Holvoet
T
, Joossens
M
, Wang
J
, Boelens
J
, Verhasselt
B
, Laukens
D
, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating
. Gut
. 2017
;66
(5
):980
–2
. 17.
Jung Lee
W
, Lattimer
LDN
, Stephen
S
, Borum
ML
, Doman
DB
. Fecal microbiota transplantation: a review of emerging indications beyond relapsing Clostridium difficile toxin colitis
. Gastroenterol Hepatol
. 2015
;11
(1
):24
–32
.18.
Simren
M
, Barbara
G
, Flint
HJ
, Spiegel
BMR
, Spiller
RC
, Vanner
S
, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report
. Gut
. 2013
;62
(1
):159
–76
. 19.
Kelly
CR
, Kahn
S
, Kashyap
P
, Laine
L
, Rubin
D
, Atreja
A
, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook
. Gastroenterology
. 2015
;149
(1
):223
–37
. 20.
Kassinen
A
, Krogius-Kurikka
L
, Mäkivuokko
H
, Rinttilä
T
, Paulin
L
, Corander
J
, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects
. Gastroenterology
. 2007
;133
(1
):24
–33
. 21.
Carroll
IM
, Chang
YH
, Park
J
, Sartor
RB
, Ringel
Y
. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
. Gut Pathog
. 2010
;2
(1
):19
. 22.
Halkjaer
SI
, Christensen
AH
, Lo
BZS
, Browne
PD
, Günther
S
, Hansen
LH
, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study
. Gut
. 2018
;67
(12
):2107
–15
. 23.
Aroniadis
OC
, Brandt
LJ
, Oneto
C
, Feuerstadt
P
, Sherman
A
, Wolkoff
AW
, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial
. Lancet Gastroenterol Hepatol
. 2019
;4
(9
):675
–85
. 24.
Lahtinen
P
, Jalanka
J
, Hartikainen
A
, Mattila
E
, Hillilä
M
, Punkkinen
J
, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome
. Aliment Pharmacol Ther
. 2020
;51
(12
):1321
–31
. 25.
Al-Hujailan
G
, Lagace-Wiens
P
. Mechanical valve endocarditis caused by Gemella morbillorum
. J Med Microbiol
. 2007
;56
(Pt 12
):1689
–91
. 26.
Torres-Morales
J
, Mark Welch
JL
, Dewhirst
FE
, Borisy
GG
. Site-specialization of human oral Gemella species
. J Oral Microbiol
. 2023
;15
(1
):2225261
. 27.
Yajima
T
. Contractile effect of short-chain fatty acids on the isolated colon of the rat
. J Physiol
. 1985
;368
:667
–78
. 28.
Canizalez-Roman
A
, Reina-Reyes
JE
, Angulo-Zamudio
UA
, Geminiano-Martínez
EE
, Flores-Carrillo
AF
, García-Matus
RR
, et al. Prevalence of cyclomodulin-positive E. coli and Klebsiella spp. strains in Mexican patients with colon diseases and antimicrobial resistance
. Pathogens
. 2021
;11
(1
):14
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
